<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03893175</url>
  </required_header>
  <id_info>
    <org_study_id>832417</org_study_id>
    <nct_id>NCT03893175</nct_id>
  </id_info>
  <brief_title>Towards Predicting the Analgesic Response to Ibuprofen Following Third-molar Extraction</brief_title>
  <official_title>Towards Predicting the Analgesic Response to Ibuprofen Following Third-molar Extraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study will evaluate inter-individual variability in the analgesic response to
      the non-steroidal anti-inflammatory drug (NSAID) ibuprofen after third molar extraction
      surgery. It will also investigate demographic, clinical, genetic, and environmental factors
      that cause this variability.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The dramatic increase in opioid prescriptions over the past years has been linked to the
      concomitant rise in opioid addiction and to deaths from opioid abuse. Young adults' initial
      exposure to opioid analgesics is often following extraction of their impacted third molars,
      with an average of 5,000,000 cases in the USA per year. Over-prescribing of opioids for
      surgical pain, often 2-5 times more than patients actually use, further exacerbates this
      problem, as patients tend to save leftover pills rather than discard them. Up to 70% of
      individuals who become addicted to prescription opioids had access to leftover pills
      prescribed for others. This is particularly troubling as the odds of transitioning to heroin
      from prescription opioid abuse are much higher than other suspected gateway drugs, about 40
      fold greater than non-gateway drug users. Heroin is now often laced with fentanyl derivatives
      making overdose and death more likely in even the most opioid tolerant individuals.

      Multiple studies have demonstrated that non-addicting nonsteroidal anti-inflammatory drugs
      (NSAIDs) such as ibuprofen and diclofenac are effective in relieving pain after dental
      impaction surgery, being at least equally efficacious to optimal doses of immediate release
      opioid formulations combined with acetaminophen. However, these assessments of pain relief
      represent average scores and approximately 22% and 50% of individuals required additional
      opioid-containing rescue analgesics when ibuprofen and diclofenac were employed at
      FDA-approved dosages. A deeper understanding of the sources of variability in pain relief
      should allow improvements in the overall efficacy of NSAIDs by targeting treatment to those
      who are most likely to receive sufficient pain relief. Thus, optimizing pain therapy with
      NSAIDs by personalization would be expected to help limit the unnecessary prescription of
      highly addicting immediate release opioids. Moreover, these results may have applicability to
      other types of pain that are driven by inflammation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 10, 2019</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects will be randomized to receive either ibuprofen or placebo after third molar extraction when pain intensity is at least 4/10.
Four hours after the masked ibuprofen or placebo, all subjects will receive open-label ibuprofen + acetaminophen to be taken every 4 hours for the first 2 days and then as needed for up to 7 days after oral surgery.
Oxycodone will be available as a rescue medication if additional analgesic is requested.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Administration of ibuprofen vs. placebo will be masked.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Analgesic response</measure>
    <time_frame>Up to 4 hours after taking blinded ibuprofen or placebo</time_frame>
    <description>Need for opioid rescue medication after administration of blinded study drug</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ibuprofen plasma concentrations</measure>
    <time_frame>Up to 7 days</time_frame>
    <description>Assessed by measuring the amount of ibuprofen in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acetaminophen plasma concentrations</measure>
    <time_frame>Up to 7 days</time_frame>
    <description>Assessed by measuring the amount of acetaminophen in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gene expression profiling</measure>
    <time_frame>Up to 7 days</time_frame>
    <description>mRNA levels will be measured in peripheral blood mononuclear cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COX-1 activity</measure>
    <time_frame>Up to 7 days</time_frame>
    <description>COX-1 activity will be measured ex vivo using a whole blood assay and in vivo by quantifying concentrations of prostaglandin metabolites in urine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COX-2 activity</measure>
    <time_frame>Up to 7 days</time_frame>
    <description>COX-2 activity will be measured ex vivo using a whole blood assay and in vivo by quantifying concentrations of prostaglandin metabolites in urine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DNA sequencing</measure>
    <time_frame>1 day</time_frame>
    <description>Assessment of genetic variation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary metabolomics</measure>
    <time_frame>Up to 7 days</time_frame>
    <description>Assessed by measuring levels of metabolites in urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma metabolomics</measure>
    <time_frame>Up to 7 days</time_frame>
    <description>Assessed by measuring levels of metabolites in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composition of the gut microbiome</measure>
    <time_frame>1 day</time_frame>
    <description>Assessed by evaluating the microbes present in a stool sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composition of the oral microbiome</measure>
    <time_frame>1 day</time_frame>
    <description>Assessed by evaluating the microbes present in an oral swab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain intensity score</measure>
    <time_frame>Up to 7 days</time_frame>
    <description>Rating of pain from 0 (no pain) to 10 (worst imaginable pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory mediator profiling</measure>
    <time_frame>Up to 7 days</time_frame>
    <description>Assessment of cytokines in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein</measure>
    <time_frame>Up to 7 days</time_frame>
    <description>Assessment C-reactive protein in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procalcitonin levels</measure>
    <time_frame>Up to 7 days</time_frame>
    <description>Assessment of procalcitonin in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete blood count with differential</measure>
    <time_frame>Up to 7 days</time_frame>
    <description>Assessment of proportions of red blood cells, white blood cells, and platelets in whole blood</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Impacted Third Molar Tooth</condition>
  <condition>Pain, Acute</condition>
  <arm_group>
    <arm_group_label>Ibuprofen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During the double-blind stage, subjects will receive blinded ibuprofen (400 mg by mouth) when pain is at least 4/10 following third molar extraction.
During the open-label stage, all subjects will receive ibuprofen (400 mg by mouth) and acetaminophen (500 mg by mouth) to be taken every 4 hours around the clock for the first 2 days after third molar extraction and then as needed for pain up to 7 days after third molar extraction.
Rescue medication (oxycodone 5 mg by mouth) will be available if additional analgesic is requested.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>During the double-blind stage, subjects will receive blinded placebo when pain is at least 4/10 following third molar extraction.
During the open-label stage, all subjects will receive ibuprofen (400 mg by mouth) and acetaminophen (500 mg by mouth) to be taken every 4 hours around the clock for the first 2 days after third molar extraction and then as needed for pain up to 7 days after third molar extraction.
Rescue medication (oxycodone 5 mg by mouth) will be available if additional analgesic is requested.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>400 mg by mouth every 4 hours for 2 days after third molar extraction and then as needed for pain up to 7 days after third molar extraction</description>
    <arm_group_label>Ibuprofen</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Advil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen</intervention_name>
    <description>500 mg by mouth every 4 hours for 2 days after third molar extraction and then as needed for pain up to 7 days after third molar extraction</description>
    <arm_group_label>Ibuprofen</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Tylenol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>By mouth</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone</intervention_name>
    <description>5 mg by mouth every 6 hours as needed for pain</description>
    <arm_group_label>Ibuprofen</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women greater than 18 years of age requiring extraction of at least one
             impacted mandibular third molar tooth (at least 50% covered with bone).

          -  Body mass index (BMI) between 18 and 30 kg/m2.

          -  Absence of other major medical problems or contraindications to surgery or study
             drugs.

          -  Has not used tobacco products, including smoking cessation nicotine-containing
             products (e.g., nicotine patch, nicotine gum), for at least the 3 months prior to
             screening.

          -  Female subjects of child bearing potential must be using a medically acceptable method
             of contraception (oral contraception, Depo-Provera injection, IUD, condom with
             spermicide, diaphragm, cervical cap, progestin implant, abstinence, tubal ligation,
             oophorectomy, TAH) throughout the entire study period. All female subjects must
             consent to a urine pregnancy test at screening and a urine pregnancy test on the day
             of surgery, which must be negative at all time points.

          -  Has not ingested caffeine-containing products within 12 hours of surgery.

          -  All subjects must consent to a urine drug test at screening. Results must be negative.
             A positive result will be reported to the subject.

          -  Does not consume more than 1 alcoholic beverage per day on average.

          -  Subjects must reach a level of at least moderate pain within four hours of surgery
             completion, with a pain score greater than or equal to 4 on a 0-10 numerical pain
             scale

          -  Subjects must be willing and able to complete safety and efficacy diaries.

          -  An escort must be available to pick up the subject at the end of at the end of the
             surgical/dosing visit (Visit #2)

          -  In the opinion of the investigators or research coordinators, subjects must be willing
             and able to understand and comply with study procedures, including completing safety
             and efficacy diaries at home.

          -  Able and willing to provide written informed consent prior to any study procedures
             being performed.

        Exclusion Criteria:

          -  Female subjects who are pregnant or nursing a child.

          -  Subjects who have received an investigational drug or used an experimental medical
             device within 30 days prior to screening, or who gave a blood donation of â‰¥ one pint
             within 8 weeks prior to screening.

          -  Subjects who are sensitive or allergic to ibuprofen, acetaminophen, or their
             components.

          -  Subjects who are sensitive or allergic to aspirin or other NSAIDs.

          -  Subjects who are sensitive or allergic to oxycodone or other opioids (excluding nausea
             and constipation).

          -  Presence of a serious medical condition (e.g. poorly controlled hypertension or
             diabetes, gastrointestinal disorders such as bleeding ulcer, coagulation or bleeding
             disorders, significantly impaired cardiac, renal, hepatic, respiratory, or thyroid
             function) that according to the investigator may interfere with interpretation of the
             study results or compromise the safety of a potential subject.

          -  Acute local infection at the time of surgery that could confound post-surgical
             evaluation.

          -  Use of any confounding prescription or non-prescription drug within 24 hours of the
             surgical procedure, including analgesics, sedating antihistamine, sedative, alcohol,
             or CNS/psychotropic agents (i.e. sleep aids, benzodiazepines, performance/attention
             enhancers, marijuana, anti-depressants). Hormonal contraceptives, hormone replacement
             therapy (including males taking testosterone as a hormone replacement to treat a
             documented low testosterone level), or thyroid replacement hormones are allowed.
             Individuals taking other/additional chronic stable medications can be considered on a
             case-by-case basis for inclusion in the study if agreed upon by judgment of the
             investigator.

          -  Subjects who have taken NSAIDs, including acetaminophen, or other medications for
             pain, including aspirin or aspirin-containing products within 1 week of study drug
             administration.

          -  Subjects who routinely consume high doses of antioxidant vitamins daily (vitamin C &gt;
             1000mg, Vitamin E &gt; 400IU, Beta Carotene &gt; 1000IU, Vitamin A &gt; 5000IU, Selenium &gt;
             200mcg, Folic Acid &gt; 1mg) during the 2 weeks prior to the start of the study.

          -  Subjects with any abnormal laboratory value or physical finding that according to the
             investigator may interfere with interpretation of the study results, be indicative of
             an underlying disease state, or compromise the safety of a potential subject.

          -  Subjects who have a history of abuse of narcotics, street drugs, prescription sleeping
             pills, based upon history and judgment of the Investigator.

          -  Subjects who are unwilling to provide a blood sample for genetic analyses.

          -  Employees of the principal investigator, sub-investigators, or relative of an employee
             who is directly involved in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tilo Grosser, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Katherine N Theken, PharmD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elliot V Hersh, DMD, MS, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Farrar, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stacey A Secreto</last_name>
    <phone>215-746-8871</phone>
    <email>secreto@upenn.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute for Translational Medicine and Therapeutics (ITMAT), University of Pennsylvania School of Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacey A Secreto</last_name>
      <phone>215-746-8871</phone>
      <email>secreto@upenn.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Friedman JW. The prophylactic extraction of third molars: a public health hazard. Am J Public Health. 2007 Sep;97(9):1554-9. Epub 2007 Jul 31.</citation>
    <PMID>17666691</PMID>
  </reference>
  <reference>
    <citation>Gauger EM, Gauger EJ, Desai MJ, Lee DH. Opioid Use After Upper Extremity Surgery. J Hand Surg Am. 2018 May;43(5):470-479. doi: 10.1016/j.jhsa.2018.02.026. Epub 2018 Mar 27. Review.</citation>
    <PMID>29602656</PMID>
  </reference>
  <reference>
    <citation>Maughan BC, Hersh EV, Shofer FS, Wanner KJ, Archer E, Carrasco LR, Rhodes KV. Unused opioid analgesics and drug disposal following outpatient dental surgery: A randomized controlled trial. Drug Alcohol Depend. 2016 Nov 1;168:328-334. doi: 10.1016/j.drugalcdep.2016.08.016. Epub 2016 Sep 20.</citation>
    <PMID>27663358</PMID>
  </reference>
  <reference>
    <citation>Thiels CA, Anderson SS, Ubl DS, Hanson KT, Bergquist WJ, Gray RJ, Gazelka HM, Cima RR, Habermann EB. Wide Variation and Overprescription of Opioids After Elective Surgery. Ann Surg. 2017 Oct;266(4):564-573. doi: 10.1097/SLA.0000000000002365.</citation>
    <PMID>28697049</PMID>
  </reference>
  <reference>
    <citation>Substance Abuse and Mental Health Services Administration (US), Office of the Surgeon General (US). Facing Addiction in America: The Surgeon General's Report on Alcohol, Drugs, and Health [Internet]. Washington (DC): US Department of Health and Human Services; 2016 Nov. Available from http://www.ncbi.nlm.nih.gov/books/NBK424857/</citation>
    <PMID>28252892</PMID>
  </reference>
  <reference>
    <citation>Compton WM, Jones CM, Baldwin GT. Relationship between Nonmedical Prescription-Opioid Use and Heroin Use. N Engl J Med. 2016 Jan 14;374(2):154-63. doi: 10.1056/NEJMra1508490. Review.</citation>
    <PMID>26760086</PMID>
  </reference>
  <reference>
    <citation>Cooper SA, Engel J, Ladov M, Precheur H, Rosenheck A, Rauch D. Analgesic efficacy of an ibuprofen-codeine combination. Pharmacotherapy. 1982 May-Jun;2(3):162-7.</citation>
    <PMID>6763202</PMID>
  </reference>
  <reference>
    <citation>Hersh EV, Levin LM, Adamson D, Christensen S, Kiersch TA, Noveck R, Watson G 2nd, Lyon JA. Dose-ranging analgesic study of Prosorb diclofenac potassium in postsurgical dental pain. Clin Ther. 2004 Aug;26(8):1215-27.</citation>
    <PMID>15476903</PMID>
  </reference>
  <reference>
    <citation>Hersh EV, Levin LM, Cooper SA, Doyle G, Waksman J, Wedell D, Hong D, Secreto SA. Ibuprofen liquigel for oral surgery pain. Clin Ther. 2000 Nov;22(11):1306-18.</citation>
    <PMID>11117655</PMID>
  </reference>
  <reference>
    <citation>Desjardins PJ, Black PM, Daniels S, Bird SR, Fitzgerald BJ, Petruschke RA, Tershakovec A, Chang DJ. A randomized controlled study comparing rofecoxib, diclofenac sodium, and placebo in post-bunionectomy pain. Curr Med Res Opin. 2004 Oct;20(10):1523-37.</citation>
    <PMID>15462686</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 22, 2019</study_first_submitted>
  <study_first_submitted_qc>March 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 28, 2019</study_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-steroidal anti-inflammatory drugs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

